GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mallinckrodt PLC (OTCPK:MCKPF) » Definitions » Market Cap

Mallinckrodt (Mallinckrodt) Market Cap : $2 Mil (As of Apr. 27, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Mallinckrodt Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Mallinckrodt's share price for the quarter that ended in Sep. 2023 was $0.08525. Mallinckrodt's Shares Outstanding (EOP) for the quarter that ended in Sep. 2023 was 13 Mil. Therefore, Mallinckrodt's market cap for the quarter that ended in Sep. 2023 was $1 Mil.

Mallinckrodt's quarterly market cap declined from Mar. 2023 ($96 Mil) to Jun. 2023 ($16 Mil) and declined from Jun. 2023 ($16 Mil) to Sep. 2023 ($1 Mil).

Mallinckrodt's annual market cap stayed the same from Dec. 2020 ($0 Mil) to Dec. 2021 ($0 Mil) but then increased from Dec. 2021 ($0 Mil) to Dec. 2022 ($102 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Mallinckrodt's Enterprise Value for Today is $-10 Mil.


Mallinckrodt Market Cap Historical Data

The historical data trend for Mallinckrodt's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mallinckrodt Market Cap Chart

Mallinckrodt Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 102.07

Mallinckrodt Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 223.91 102.07 96.02 15.68 1.14

Competitive Comparison of Mallinckrodt's Market Cap

For the Drug Manufacturers - Specialty & Generic subindustry, Mallinckrodt's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mallinckrodt's Market Cap Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mallinckrodt's Market Cap distribution charts can be found below:

* The bar in red indicates where Mallinckrodt's Market Cap falls into.



Mallinckrodt Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Mallinckrodt's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as

Market Cap (A: Dec. 2022 )=Share Price (A: Dec. 2022 )*Shares Outstanding (EOP) (A: Dec. 2022 )
=$7.75*13.1709
=$

Mallinckrodt's Market Cap for the quarter that ended in Sep. 2023 is calculated as

Market Cap (Q: Sep. 2023 )=Share Price (Q: Sep. 2023 )*Shares Outstanding (EOP) (Q: Sep. 2023 )
=$0.08525*13.3573
=$1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mallinckrodt  (OTCPK:MCKPF) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Mallinckrodt Market Cap Related Terms

Thank you for viewing the detailed overview of Mallinckrodt's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Mallinckrodt (Mallinckrodt) Business Description

Traded in Other Exchanges
N/A
Address
College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, IRL, 15
Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.
Executives
Alta Fundamental Advisers Llc 10 percent owner 1500 BROADWAY, SUITE 704, NEW YORK NY 10036
Jason Daniel Goodson officer: EVP & Head of Corp Development 106 CENTRAL PARK AVENUE, WENTZVILLE MO 63885
James R Sulat director
Paul Bisaro director
Sigurdur O Olafsson director, officer: President and CEO 360 MOUNT KEMBLE AVENUE, MORRISTOWN NJ 07960
Stephen Andrew Welch officer: EVP & Head of Spec Generics 18440 BRIDGEMORE LANE, LOUISVILLE KY 40245
Peter C Richardson officer: EVP & Chief Scientific Officer 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Susan Michele Silbermann director C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Lisa French officer: EVP & Chief Commercial Officer 301 CONTINENTAL LANE, PAOLI PA 19301
Mark Anthony Tyndall officer: EVP & Chief Legal Offi & Secre 1101 Q ST NW, WASHINGTON DC 20009
Henriette Nielsen officer: EVP & Chief Transformation OFC 202 WEST 85TH STREET, APT. 5, NEW YORK NY 10024
Karen Ling director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Anne Clem Whitaker director 109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
Olifant Luxco S.a R.l. 10 percent owner 19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Paul Rutherford Carter director SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF

Mallinckrodt (Mallinckrodt) Headlines

From GuruFocus